SRR6013565
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.490
- PROTEIN_SECRETION+0.490
- INTERFERON_ALPHA_RESPONSE+0.450
- FATTY_ACID_METABOLISM+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- XENOBIOTIC_METABOLISM+0.380
- MTORC1_SIGNALING+0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.360
- GLYCOLYSIS+0.350
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- APICAL_JUNCTION-0.320
- APICAL_SURFACE-0.300
- MYOGENESIS-0.280
- TNFA_SIGNALING_VIA_NFKB-0.270
- WNT_BETA_CATENIN_SIGNALING-0.260
- ANGIOGENESIS-0.250
- ALLOGRAFT_REJECTION-0.200
- IL6_JAK_STAT3_SIGNALING-0.200
- NOTCH_SIGNALING-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR17866853 | — | — | 0.838 |
| 2 | 81b828aa-cb06-4790-ba3e-efaa39f4eeef | — | — | 0.832 |
| 3 | C3L-01862 | — | cohortA4 | 0.823 |
| 4 | AUR-ADCB-TTM1-A-1-1-R-A742-41 | — | C | 0.822 |
| 5 | 3fca0833-b19b-47af-b75e-c9c45a99373b | — | — | 0.815 |
| 6 | BS_W80TJC27 | Supratentorial Ependymoma | — | 0.813 |
| 7 | TCGA-C8-A26V-01A-11R-A16F-07 | — | B | 0.812 |
| 8 | 8824c0fd-764e-4525-952b-f25efa742772 | — | — | 0.810 |
| 9 | TCGA-A2-A0YT-01A-11R-A109-07 | — | B | 0.807 |
| 10 | c7aea5a2-5772-4475-8ca6-326193eeb69e | — | — | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.490 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.380 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.350 | Inavolisib | — uncovered |
| PEROXISOME | 0.330 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.290 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |